Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sosei Group ( (JP:4565) ) has shared an update.
Nxera Pharma reported significant achievements in 2024, including the successful launch of PIVLAZ™ and QUVIVIQ™ in Japan, contributing to substantial revenue growth. The company is advancing its clinical pipeline with late-stage trials and forging strategic partnerships, positioning it as a leader in the biopharmaceutical sector. The expansion into South Korea and collaborations with tech companies highlight Nxera’s commitment to innovation and market expansion.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing and bringing new medicines to patients in Japan and globally. The company operates within the biopharmaceutical industry, with a focus on neurology, neuropsychiatry, metabolic diseases, immunology, and inflammation. Key products include PIVLAZ™ and QUVIVIQ™, and the company is expanding its market presence in Asia.
YTD Price Performance: -1.67%
Average Trading Volume: 614
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $585.8M
See more insights into 4565 stock on TipRanks’ Stock Analysis page.
